Bile acid receptor 3D structures
From Proteopedia
(Difference between revisions)
| (8 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | *hFXR LBD complex | + | ==3D structures of bile acid receptor== |
| + | |||
| + | Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | ||
| + | {{#tree:id=OrganizedByTopic|openlevels=0| | ||
| + | |||
| + | *hFXR LBD residues 245-486 complex | ||
**[[1osh]], [[3fli]], [[3l1b]] – hFXR LBD + non-steroidal agonist - human <br /> | **[[1osh]], [[3fli]], [[3l1b]] – hFXR LBD + non-steroidal agonist - human <br /> | ||
**[[5q0i]] – hFXR LBD + PPAR gamma coactivator peptide<br /> | **[[5q0i]] – hFXR LBD + PPAR gamma coactivator peptide<br /> | ||
| - | + | **[[3fxv]], [[3gd2]], [[3okh]], [[3oki]], [[3olf]], [[3omk]], [[3omm]], [[1ot7]] – hFXR LBD + CDC derivative + RPGR-interacting protein peptide<br /> | |
| - | **[[3fxv]], [[3gd2]], [[3okh]], [[3oki]], [[3olf]], [[3omk]], [[3omm]], | + | |
| - | [[1ot7]] – hFXR LBD + CDC derivative + RPGR-interacting protein peptide<br /> | + | |
**[[4oiv]] – hFXR LBD + antagonist <br /> | **[[4oiv]] – hFXR LBD + antagonist <br /> | ||
| - | |||
*hFXR LBD complex with nuclear receptor corepressor 1 | *hFXR LBD complex with nuclear receptor corepressor 1 | ||
| - | **[[4wvd]] - hFXR LBD + NCOA1 peptide<br /> | + | **[[4wvd]], [[5q0w]], [[5q15]], [[5wzx]], [[5q0j]], [[5q0k]], [[5q0l]], [[5q0m]], [[5q0n]], [[5q0o]], [[5q0p]], [[5q0q]], [[5q0r]], [[5q0s]], [[5q0t]], [[5q0u]], [[5q0v]], [[5q0x]], [[5q0y]], [[5q0z]], [[5q10]], [[5q11]], [[5q12]], [[5q13]], [[5q14]], [[5q16]], [[5q17]], [[5q18]], [[5q19]], [[5q1a]], [[5q1b]], [[5q1c]], [[5q1d]], [[5q1e]], [[5q1f]], [[5q1g]], [[5q1h]], [[5q1i]] - hFXR LBD + NCOA1 peptide<br /> |
| - | **[[3bej]], [[3dct]], [[3dcu]], [[3hc5]], [[3hc6]], [[3rut]], [[3ruu]], [[3rvf]] – hFXR LBD + non-steroidal agonist + NCOA1 peptide<br /> | + | **[[3bej]], [[3dct]], [[3dcu]], [[3hc5]], [[3hc6]], [[3rut]], [[3ruu]], [[3rvf]], [[6itm]] – hFXR LBD + non-steroidal agonist + NCOA1 peptide<br /> |
**[[6a5w]] - hFXR LBD + thiazole derivative + NCOA1 peptide<br /> | **[[6a5w]] - hFXR LBD + thiazole derivative + NCOA1 peptide<br /> | ||
**[[6a5x]] - hFXR LBD (mutant) + thiazole derivative + NCOA1 peptide<br /> | **[[6a5x]] - hFXR LBD (mutant) + thiazole derivative + NCOA1 peptide<br /> | ||
| Line 22: | Line 24: | ||
*hFXR LBD complex with nuclear receptor corepressor 2 | *hFXR LBD complex with nuclear receptor corepressor 2 | ||
| + | **[[5iaw]], [[6hl0]] - hFXR LBD + NCOA2 peptide<br /> | ||
**[[1osv]] – hFXR LBD + CDC derivative + NCOA2 peptide<br /> | **[[1osv]] – hFXR LBD + CDC derivative + NCOA2 peptide<br /> | ||
**[[5z12]] - hFXR LBD (mutant) + indole derivative + NCOA2 peptide + RXR-a + retinoic acid<br /> | **[[5z12]] - hFXR LBD (mutant) + indole derivative + NCOA2 peptide + RXR-a + retinoic acid<br /> | ||
| - | **[[ | + | **[[6hl1]] – hFXR LBD + CDC + NCOA2 peptide<br /> |
**[[5ick]] – hFXR LBD + feroline + NCOA2 peptide<br /> | **[[5ick]] – hFXR LBD + feroline + NCOA2 peptide<br /> | ||
| - | **[[5y1j]] – hFXR LBD + drug + NCOA2 peptide<br /> | + | **[[5y1j]], [[7d42]], [[7vue]] – hFXR LBD + drug + NCOA2 peptide<br /> |
**[[5y49]] – hFXR LBD + moderator + NCOA2 peptide<br /> | **[[5y49]] – hFXR LBD + moderator + NCOA2 peptide<br /> | ||
**[[5yxb]], [[5yxd]], [[5yxj]], [[5yxl]] – hFXR LBD + pyridine derivative + NCOA2 peptide<br /> | **[[5yxb]], [[5yxd]], [[5yxj]], [[5yxl]] – hFXR LBD + pyridine derivative + NCOA2 peptide<br /> | ||
| + | **[[7trb]] – hFXR LBD + inhibitor + NCOA2 peptide<br /> | ||
**[[4qe8]] – hFXR LBD + DM175 + NCOA2 peptide<br /> | **[[4qe8]] – hFXR LBD + DM175 + NCOA2 peptide<br /> | ||
| + | **[[8hbm]] - hFXR 127-227 + RXR-a <br /> | ||
}} | }} | ||
| + | |||
| + | [[Category:Topic Page]] | ||
Current revision
3D structures of bile acid receptor
Updated on 10-December-2024
